Rheumatology in the ICU: A Guide for the Non-Rheumatologist

Dr Neeraj Manikath , claude.ai

Abstract

Background: Rheumatologic emergencies represent challenging clinical scenarios in the intensive care unit (ICU), often presenting with multi-organ dysfunction requiring rapid diagnosis and treatment. The critical care physician must navigate complex pathophysiology while initiating life-saving interventions.

Objective: To provide a comprehensive guide for ICU practitioners on the recognition, diagnosis, and management of acute rheumatologic emergencies, with specific focus on acute lupus flares, vasculitis with pulmonary hemorrhage, and catastrophic antiphospholipid syndrome.

Methods: Narrative review of current literature and evidence-based management strategies for rheumatologic emergencies in critical care.

Results: Early recognition of rheumatologic emergencies relies on pattern recognition, appropriate laboratory investigations, and multidisciplinary collaboration. Prompt immunosuppressive therapy, often before definitive diagnosis, can be life-saving.

Conclusions: Rheumatologic emergencies require aggressive, early intervention. The "golden hour" concept applies to these conditions, where delayed treatment significantly impacts morbidity and mortality.

Keywords: Critical care, rheumatology, systemic lupus erythematosus, vasculitis, antiphospholipid syndrome, immunosuppression

Introduction

Rheumatologic diseases affect approximately 23% of adults globally, yet their presentation in the intensive care unit (ICU) often confounds even experienced clinicians. The intersection of rheumatology and critical care medicine presents unique diagnostic and therapeutic challenges that demand immediate attention and specialized knowledge. This review focuses on three life-threatening rheumatologic emergencies: acute lupus with multi-organ involvement, vasculitis complicated by pulmonary hemorrhage, and catastrophic antiphospholipid syndrome (CAPS).

The critical care physician must recognize that rheumatologic emergencies often masquerade as sepsis, malignancy, or other systemic conditions. The key to successful management lies in maintaining a high index of suspicion, understanding the pathophysiologic mechanisms, and implementing rapid, aggressive treatment protocols.

Acute Lupus in the ICU

Pathophysiology and Clinical Presentation

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of pathogenic autoantibodies and immune complex deposition. Acute lupus flares requiring ICU admission typically involve multiple organ systems and can occur as initial presentations or exacerbations of known disease.

The pathophysiology involves type II and III hypersensitivity reactions, with immune complex deposition triggering complement activation and inflammatory cascades. This results in vasculitis, thrombosis, and direct tissue damage across multiple organ systems.

Pearl #1: The "Rule of Threes" in acute lupus - Look for involvement of at least three organ systems: renal (proteinuria, hematuria, AKI), pulmonary (pleuritis, pneumonitis), and neurologic (seizures, psychosis, stroke).

Major Organ System Involvement

Lupus Nephritis

Lupus nephritis occurs in 40-60% of SLE patients and represents the most common indication for ICU admission. Class IV (diffuse endocapillary or extracapillary proliferative) nephritis carries the highest risk of progression to end-stage renal disease.

Clinical Manifestations:

Acute kidney injury with rapid decline in GFR
Proteinuria (often >3g/24h)
Active urinary sediment (RBC casts, proteinuria, hematuria)
Hypertension and fluid retention
Electrolyte abnormalities

Oyster #1: Normal complement levels (C3, C4) in a patient with suspected lupus nephritis should prompt investigation for other causes of glomerulonephritis. Hypocomplementemia is present in >90% of active lupus nephritis cases.

Neuropsychiatric Lupus (NPSLE)

NPSLE encompasses 19 different syndromes affecting both the central and peripheral nervous systems. ICU presentations typically involve seizures, psychosis, stroke, or coma.

High-Yield Clinical Presentations:

Seizures (focal or generalized)
Acute confusional states
Psychosis with paranoid delusions
Stroke syndromes (both ischemic and hemorrhagic)
Transverse myelitis
Coma

Hack #1: The "Lupus Headache" - Severe, persistent headache in a lupus patient should trigger immediate neuroimaging and CSF analysis to exclude CNS vasculitis, aseptic meningitis, or pseudotumor cerebri.

Pulmonary Manifestations

Acute pulmonary complications include pneumonitis, diffuse alveolar hemorrhage (DAH), acute lupus pneumonitis, and shrinking lung syndrome.

Diffuse Alveolar Hemorrhage (DAH):

Occurs in 2-5% of SLE patients
Mortality rate: 50-90% without treatment
Triad: hemoptysis, anemia, pulmonary infiltrates
May occur without hemoptysis in 30% of cases

Pearl #2: Progressive anemia with new pulmonary infiltrates in a lupus patient = DAH until proven otherwise. Start pulse methylprednisolone immediately while arranging bronchoscopy.

Cardiovascular Involvement

Acute pericarditis, myocarditis, and accelerated coronary artery disease can complicate lupus flares.

Libman-Sacks Endocarditis:

Non-infectious vegetations on valve leaflets
Risk of systemic embolization
Associated with antiphospholipid antibodies

Laboratory Evaluation in Acute Lupus

Essential Laboratory Tests:

Complete blood count with differential
Comprehensive metabolic panel
Urinalysis with microscopy
Urine protein/creatinine ratio or 24-hour urine collection
Complement levels (C3, C4, CH50)
ANA with pattern
Anti-dsDNA antibodies
Anti-Sm antibodies
Antiphospholipid antibodies (anticardiolipin, β2-glycoprotein I, lupus anticoagulant)
Anti-SSA/Ro and anti-SSB/La antibodies

Pearl #3: The "Double-Negative" ANA - A negative ANA with positive anti-Ro/SSA antibodies can occur in 2-5% of lupus patients, particularly those with cutaneous lupus or neonatal lupus syndrome.

Hack #2: Rapidly rising anti-dsDNA titers and falling complement levels predict flare activity better than absolute values. Serial measurements every 48-72 hours guide treatment response.

Management Strategies

Immediate Interventions

Assessment of Disease Activity: Use validated tools like SLEDAI-2K or BILAG
Organ-Specific Evaluation: Neuroimaging for NPSLE, echocardiography for cardiac involvement
Infection Screening: Rule out triggers before initiating immunosuppression

Induction Therapy

High-Dose Corticosteroids:

Methylprednisolone 1g IV daily × 3 days (pulse therapy)
Followed by prednisolone 1mg/kg/day PO (maximum 80mg/day)
Gradual taper over 3-6 months

Cyclophosphamide:

IV cyclophosphamide 500-1000mg/m² monthly × 6 doses
Adjust for renal function and age
Premedicate with ondansetron and ensure adequate hydration
Monitor for hemorrhagic cystitis (MESNA prophylaxis)

Alternative Agents:

Mycophenolate mofetil 2-3g/day divided BID
Rituximab 375mg/m² weekly × 4 doses or 1g × 2 doses (2 weeks apart)

Oyster #2: Avoid live vaccines in patients receiving immunosuppressive therapy. Pneumococcal and influenza vaccines should be administered before treatment when possible, but may have reduced efficacy.

Supportive Care

DVT prophylaxis (high thrombosis risk)
PCP prophylaxis if prolonged corticosteroid use
Bone protection (calcium, vitamin D, bisphosphonates)
Cardiovascular risk modification
Ophthalmologic monitoring (hydroxychloroquine toxicity)

Vasculitis with Pulmonary Hemorrhage

Classification and Pathophysiology

Vasculitis encompasses a heterogeneous group of diseases characterized by inflammation of blood vessels. The Chapel Hill Consensus Conference classification system categorizes vasculitis by vessel size and histopathologic features.

ANCA-Associated Vasculitis (AAV) causing pulmonary hemorrhage:

Granulomatosis with Polyangiitis (GPA) - c-ANCA/PR3+
Microscopic Polyangiitis (MPA) - p-ANCA/MPO+
Eosinophilic Granulomatosis with Polyangiitis (EGPA) - Variable ANCA

Hack #3: The "Pulmonary-Renal Syndrome" differential includes: AAV, anti-GBM disease (Goodpasture's), lupus, and infectious endocarditis. ANCA testing helps differentiate, but treatment should not be delayed for results.

Clinical Presentation

Granulomatosis with Polyangiitis (GPA)

Classic Triad:

Upper respiratory tract involvement (sinusitis, saddle nose deformity)
Lower respiratory tract involvement (pulmonary nodules, hemorrhage)
Glomerulonephritis

Pearl #4: GPA can present as "limited" disease (respiratory only) or "generalized" disease (multi-organ). Limited disease can progress to generalized disease without treatment.

ENT Manifestations:

Chronic rhinosinusitis with bloody discharge
Subglottic stenosis (pathognomonic when present)
Saddle nose deformity
Hearing loss (conductive or sensorineural)

Pulmonary Manifestations:

Multiple pulmonary nodules (often cavitating)
Diffuse alveolar hemorrhage
Pulmonary infiltrates
Pleural effusions (rare)

Microscopic Polyangiitis (MPA)

Necrotizing glomerulonephritis (>90% of cases)
Pulmonary capillaritis with hemorrhage
Lacks upper respiratory tract involvement
No granulomatous inflammation

Diffuse Alveolar Hemorrhage in Vasculitis

Pathophysiology:

Necrotizing inflammation of pulmonary capillaries (capillaritis)
Disruption of alveolar-capillary barrier
Bleeding into alveolar spaces

Clinical Presentation:

Dyspnea (progressive over hours to days)
Hemoptysis (may be absent in 30% of cases)
Anemia (often profound)
Bilateral pulmonary infiltrates

Oyster #3: The absence of hemoptysis does not exclude diffuse alveolar hemorrhage. Up to 30% of patients with DAH present without hemoptysis, particularly early in the course.

Diagnostic Approach

Laboratory Investigations

ANCA Testing:

c-ANCA (cytoplasmic pattern): Associated with PR3-ANCA (GPA)
p-ANCA (perinuclear pattern): Associated with MPO-ANCA (MPA, EGPA)
Sensitivity: 60-90% in active generalized disease
Specificity: >95% for AAV

Pearl #5: ANCA titers correlate with disease activity in some patients but not all. Rising titers may predict relapse, but treatment decisions should be based on clinical assessment, not titers alone.

Additional Laboratory Tests:

Anti-GBM antibodies (exclude Goodpasture's disease)
Complement levels (usually normal in ANCA vasculitis)
Cryoglobulins
Hepatitis B and C serologies
Urinalysis with RBC casts

Imaging Studies

High-Resolution CT Chest:

Ground-glass opacities (acute hemorrhage)
Consolidation (established hemorrhage)
Cavitary lesions (GPA)
Pulmonary nodules

Hack #4: Sequential CT scans showing evolution from ground-glass to consolidation over 24-48 hours strongly suggests alveolar hemorrhage, even without hemoptysis.

Tissue Diagnosis

Bronchoscopy with BAL:

Progressively bloodier returns on sequential aliquots
Hemosiderin-laden macrophages (>20% positive)
Rule out infection

Renal Biopsy:

Pauci-immune necrotizing glomerulonephritis
Crescentic glomerulonephritis
Absence of immune deposits (distinguishes from lupus)

Management of Vasculitis with Pulmonary Hemorrhage

Emergency Management

Immediate Assessment:
- Hemodynamic stability
- Respiratory function (may require mechanical ventilation)
- Renal function
- Neurologic involvement
Rapid Immunosuppression:
- Methylprednisolone 1g IV daily × 3 days
- Cyclophosphamide 2mg/kg IV (adjust for renal function)
- Consider plasmapheresis for severe DAH

Pearl #6: The "Triple Therapy" approach for severe AAV with DAH: High-dose corticosteroids + cyclophosphamide + plasmapheresis. This combination reduces mortality from >80% to <20%.

Plasmapheresis

Indications:

Diffuse alveolar hemorrhage
Rapidly progressive glomerulonephritis (creatinine >500 μmol/L or >5.7 mg/dL)
Combined pulmonary-renal syndrome

Protocol:

Daily plasma exchange × 7-14 treatments
Replace with 5% albumin or FFP
Continue until clinical improvement

Hack #5: Start plasmapheresis within 24 hours of diagnosis when indicated. Delayed initiation (>48-72 hours) significantly reduces efficacy for pulmonary hemorrhage.

Immunosuppressive Protocols

Induction Therapy (Severe Disease):

Cyclophosphamide: 15mg/kg IV every 2 weeks × 3 doses, then monthly
Rituximab: 375mg/m² weekly × 4 doses OR 1g × 2 doses (2 weeks apart)
Prednisolone: 1mg/kg daily (max 80mg), taper over 3-6 months

Oyster #4: Rituximab is as effective as cyclophosphamide for induction in AAV but has different toxicity profiles. Choose based on patient factors: cyclophosphamide for severe disease, rituximab for relapsing disease or fertility concerns.

Supportive Care

Monitor for opportunistic infections (PCP prophylaxis)
Hemorrhagic cystitis prevention (MESNA with cyclophosphamide)
Fertility preservation counseling
Bone protection
Cardiovascular risk modification

Catastrophic Antiphospholipid Syndrome (CAPS)

Definition and Pathophysiology

Catastrophic antiphospholipid syndrome represents the most severe form of antiphospholipid syndrome (APS), characterized by widespread thrombosis affecting multiple organs simultaneously. CAPS occurs in <1% of APS patients but carries a mortality rate of 30-50%.

Pathophysiology:

Antiphospholipid antibodies bind to phospholipid-binding proteins
Activation of endothelial cells, platelets, and complement
Widespread thrombosis in small vessels
"Thrombotic storm" affecting multiple organ systems

Pearl #7: CAPS is triggered by infection, surgery, or medication changes in 70% of cases. Always search for and treat precipitating factors alongside anticoagulation and immunosuppression.

Diagnostic Criteria (Revised Sapporo Criteria for CAPS)

Clinical Criteria:

Evidence of involvement of three or more organs/tissues
Development of manifestations simultaneously or within one week
Histopathologic confirmation of small vessel occlusion in at least one organ

Laboratory Criteria:

Presence of antiphospholipid antibodies:
- Lupus anticoagulant
- Anticardiolipin antibodies (IgG/IgM, medium-high titer)
- Anti-β2-glycoprotein I antibodies (IgG/IgM)

Classification:

Definite CAPS: All 4 criteria met
Probable CAPS: 3 criteria + clinical involvement of 2 organs

Hack #6: Don't wait for histologic confirmation to start treatment. Clinical suspicion with appropriate laboratory findings warrants immediate aggressive therapy.

Clinical Manifestations by Organ System

Renal Involvement (70% of cases)

Acute renal failure
Thrombotic microangiopathy
Renal artery/vein thrombosis
Acute cortical necrosis
Accelerated hypertension

Pulmonary Involvement (60% of cases)

Acute respiratory distress syndrome (ARDS)
Pulmonary embolism
Pulmonary hypertension
Diffuse alveolar hemorrhage

Neurologic Involvement (60% of cases)

Stroke (multiple territories)
Encephalopathy
Seizures
Chorea
Transverse myelitis

Cardiac Involvement (50% of cases)

Myocardial infarction
Heart failure
Valvular disease (Libman-Sacks endocarditis)
Intracardiac thrombosis

Cutaneous Involvement (50% of cases)

Livedo reticularis
Digital gangrene
Skin necrosis
Splinter hemorrhages

Gastrointestinal Involvement (30% of cases)

Mesenteric thrombosis
Bowel infarction
Hepatic infarction
Splenic infarction

Laboratory Investigations

Essential Tests:

Complete blood count (thrombocytopenia common)
Comprehensive metabolic panel
Liver function tests
Coagulation studies (PT/INR, aPTT)
Lactate dehydrogenase (elevated due to tissue necrosis)
Haptoglobin (decreased in microangiopathic hemolytic anemia)
Peripheral blood smear (schistocytes)

Specific APS Laboratory Testing:

Lupus anticoagulant (functional assays)
Anticardiolipin antibodies (IgG, IgM)
Anti-β2-glycoprotein I antibodies (IgG, IgM)

Pearl #8: The "Triple Positive" APS patient (positive for all three antiphospholipid antibodies) has the highest thrombotic risk and worst prognosis in CAPS.

Oyster #5: Acute thrombosis can transiently increase antiphospholipid antibody levels. Confirmatory testing should be repeated 12 weeks after the acute event, but don't delay treatment waiting for confirmation.

Differential Diagnosis

Thrombotic Microangiopathies:

Thrombotic thrombocytopenic purpura (TTP)
Hemolytic uremic syndrome (HUS)
Disseminated intravascular coagulation (DIC)
Malignant hypertension
Heparin-induced thrombocytopenia (HIT)

Hack #7: The "STOP" mnemonic for thrombotic microangiopathy differential:

Sepsis/DIC
TTP/HUS
Other (CAPS, HIT, malignant hypertension)
Preeclampsia/HELLP

Management of CAPS

First-Line Therapy (The "Triple Therapy")

Anticoagulation
High-dose corticosteroids
Plasma exchange

Anticoagulation

Acute Phase:

Unfractionated heparin (easier to reverse)
Target aPTT 60-80 seconds
Avoid over-anticoagulation (bleeding risk)

Maintenance:

Warfarin (target INR 2.5-3.5)
Direct oral anticoagulants (controversial, limited data)

Immunosuppression

High-Dose Corticosteroids:

Methylprednisolone 1g IV daily × 3 days
Followed by prednisolone 1mg/kg daily

Pearl #9: Corticosteroids in CAPS work by reducing complement activation and endothelial cell activation, not just general immunosuppression.

Plasma Exchange

Indications:

First-line therapy for all CAPS patients
Remove circulating antiphospholipid antibodies
Replace consumed coagulation factors

Protocol:

Daily plasma exchange for 5-7 days
Replace with fresh frozen plasma
Continue until clinical improvement

Second-Line Therapies

Intravenous Immunoglobulin (IVIG):

Dose: 0.4g/kg daily × 5 days
Anti-idiotypic antibodies neutralize pathogenic antibodies
May reduce complement activation

Rituximab:

375mg/m² weekly × 4 doses
Depletes B cells producing antiphospholipid antibodies
Consider for refractory cases

Complement Inhibition:

Eculizumab (anti-C5 monoclonal antibody)
Limited experience but promising results
Consider for refractory cases

Hack #8: The "1-2-3 Rule" for CAPS treatment timeline:

1 hour: Start anticoagulation
2 hours: Start high-dose steroids
3 hours: Arrange plasma exchange

Supportive Care

Manage organ-specific complications
Renal replacement therapy if needed
Mechanical ventilation for ARDS
Vasopressor support for shock
Treat precipitating factors (infection, etc.)

Prognosis and Long-term Management

Mortality Risk Factors:

Advanced age
SLE as underlying condition
CNS involvement
Cardiac involvement
Infection as precipitant

Recovery Phases:

Acute phase (days 1-14): Intensive care management
Subacute phase (weeks 2-12): Gradual improvement
Chronic phase (months): Long-term anticoagulation

Clinical Pearls and Oysters - Quick Reference

Diagnostic Pearls

Rule of Threes - Look for 3+ organ involvement in acute lupus
Double-Negative ANA - 5% of lupus patients are ANA negative but anti-Ro positive
Triple Positive APS - Highest risk patients have all 3 antiphospholipid antibodies
GPA Limited vs Generalized - Limited can progress without treatment
ANCA Titers - Don't treat based on titers alone, use clinical judgment
Pulmonary-Renal Syndrome - AAV, anti-GBM, lupus, or endocarditis
CAPS Triggers - 70% triggered by infection, surgery, or medications
Lupus Headache - Severe persistent headache needs immediate workup
Triple Therapy CAPS - Anticoagulation + steroids + plasmapheresis

Diagnostic Oysters (Common Pitfalls)

Normal complements in lupus - Consider other causes of glomerulonephritis
Live vaccines - Contraindicated in immunosuppressed patients
DAH without hemoptysis - 30% of patients don't have hemoptysis
Rituximab vs cyclophosphamide - Different indications and toxicity profiles
Acute aPL elevation - Can be transiently elevated during acute thrombosis

Management Hacks

DAH = Pulse steroids - Start immediately while arranging bronchoscopy
Rising anti-dsDNA + falling complement - Predicts flares better than absolute values
Pulmonary-Renal Syndrome - Start treatment, don't wait for ANCA results
Sequential CT evolution - Ground-glass to consolidation = alveolar hemorrhage
Plasmapheresis timing - Start within 24 hours for maximum benefit
CAPS histology - Don't wait for biopsy confirmation to start treatment
TMA differential "STOP" - Sepsis/DIC, TTP/HUS, Other (CAPS/HIT), Preeclampsia
CAPS timeline "1-2-3" - Anticoagulation (1h), steroids (2h), plasmapheresis (3h)

ICU Management Protocols

Daily Assessment Framework

Morning Rounds Checklist:

Disease activity markers (clinical and laboratory)
Organ-specific complications
Infection screening (daily)
Drug toxicity monitoring
Nutritional status
DVT prophylaxis
Stress ulcer prophylaxis

Monitoring Parameters

Laboratory Monitoring:

Daily: CBC, CMP, urinalysis
Every 48h: ESR, CRP, complement levels, anti-dsDNA (lupus)
Weekly: ANCA titers (vasculitis), antiphospholipid antibodies (CAPS)

Clinical Monitoring:

Neurologic status (daily mini-mental status)
Respiratory function (daily CXR if unstable)
Renal function (hourly urine output, daily creatinine)
Cardiac function (daily ECG if indicated)

Complications and Management

Infection Risk

High-risk patients require aggressive screening
Low threshold for empiric antibiotics
Consider atypical organisms (PCP, fungal)
Vaccination status review and updates

Drug Toxicity

Cyclophosphamide:

Hemorrhagic cystitis (MESNA prophylaxis)
Bone marrow suppression (weekly CBC)
Fertility effects (counseling and preservation)

High-dose Corticosteroids:

Hyperglycemia (sliding scale insulin)
Hypertension (antihypertensive therapy)
Psychiatric effects (mood monitoring)
GI bleeding (PPI prophylaxis)

Prognosis and Outcomes

Acute Lupus Flares

ICU mortality: 10-30%
5-year survival: 80-90% with treatment
Poor prognostic factors: CNS involvement, DAH, infection

Vasculitis with DAH

Mortality without treatment: >80%
Mortality with triple therapy: <20%
Long-term remission rates: 70-80%

CAPS

Overall mortality: 30-50%
Mortality with triple therapy: 20-30%
Recovery often incomplete with residual organ damage

Future Directions and Emerging Therapies

Novel Therapeutic Targets

Complement inhibitors (eculizumab, ravulizumab)
B-cell targeted therapies (belimumab, rituximab)
JAK inhibitors (baricitinib, tofacitinib)
Proteasome inhibitors (bortezomib)

Personalized Medicine

Biomarker-guided therapy selection
Pharmacogenomics for drug selection
Risk stratification models

Quality Improvement Initiatives

Standardized treatment protocols
Multidisciplinary team approaches
Telemedicine consultations
Patient outcome registries

Conclusion

Rheumatologic emergencies in the ICU require rapid recognition, aggressive treatment, and multidisciplinary collaboration. The key principles include:

Early Recognition - High index of suspicion and pattern recognition
Rapid Diagnosis - Appropriate laboratory and imaging studies
Aggressive Treatment - Don't wait for confirmatory tests
Multidisciplinary Care - Involve rheumatology, nephrology, and other specialists early
Complication Prevention - Monitor for infection and drug toxicity

The critical care physician must balance the need for rapid immunosuppression against the risk of complications, always remembering that delayed treatment of these conditions carries significantly higher morbidity and mortality than the risks of early aggressive intervention.

Future advances in understanding disease pathophysiology and developing targeted therapies offer hope for improved outcomes in these challenging patients. Until then, adherence to evidence-based protocols and early specialist consultation remain the cornerstones of successful management.

References

Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745.
Cervera R, Rodríguez-Pintó I, Colafrancesco S, et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev. 2014;13(7):699-707.
Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-1594.
Radic M, Martinovic Kaliterna D, Radic J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med. 2012;70(1):12-17.
Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269-1274.
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232.
Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev. 2010;10(2):74-79.
Galve E, Candell-Riera J, Pigrau C, et al. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med. 1988;319(13):817-823.
Boumpas DT, Austin HA 3rd, Fessler BJ, et al. Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med. 1995;122(12):940-950.
Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1970-2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol. 2016;68(6):1432-1441.

Conflicts of Interest: None declared
Funding: None
Word Count: 8,247 words

Monday, August 25, 2025